The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth ...

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderate to severe active Crohn’s disease (CD). The approval marks the ...

Tremfya-treated patients achieved statistically significant clinical remission and endoscopic response compared with placebo at weeks 0, 4, and 8. HealthDay News — The US Food and Drug ...

March 24, 2025 – The FDA has approved a new Crohn’s disease treatment called guselkumab, which, unlike similar drugs, can be given via self-injection by patients at home, provided their ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease, according to findings published in Science Immunology on March 21.The ...